JP2020122023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020122023A5 JP2020122023A5 JP2020089453A JP2020089453A JP2020122023A5 JP 2020122023 A5 JP2020122023 A5 JP 2020122023A5 JP 2020089453 A JP2020089453 A JP 2020089453A JP 2020089453 A JP2020089453 A JP 2020089453A JP 2020122023 A5 JP2020122023 A5 JP 2020122023A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- unit
- subscript
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CNc(c(*)c(COC)c(*)c1*)c1O* Chemical compound CNc(c(*)c(COC)c(*)c1*)c1O* 0.000 description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022007056A JP7431261B2 (ja) | 2012-05-15 | 2022-01-20 | 自己安定化リンカー結合体 |
| JP2024014096A JP2024032941A (ja) | 2012-05-15 | 2024-02-01 | 自己安定化リンカー結合体 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647373P | 2012-05-15 | 2012-05-15 | |
| US61/647,373 | 2012-05-15 | ||
| US201361770983P | 2013-02-28 | 2013-02-28 | |
| US61/770,983 | 2013-02-28 | ||
| US201361773067P | 2013-03-05 | 2013-03-05 | |
| US61/773,067 | 2013-03-05 | ||
| US13/799,244 US9504756B2 (en) | 2012-05-15 | 2013-03-13 | Self-stabilizing linker conjugates |
| US13/799,244 | 2013-03-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018097123A Division JP6709247B2 (ja) | 2012-05-15 | 2018-05-21 | 自己安定化リンカー結合体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007056A Division JP7431261B2 (ja) | 2012-05-15 | 2022-01-20 | 自己安定化リンカー結合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020122023A JP2020122023A (ja) | 2020-08-13 |
| JP2020122023A5 true JP2020122023A5 (https=) | 2020-09-24 |
| JP7014856B2 JP7014856B2 (ja) | 2022-02-01 |
Family
ID=49584442
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512756A Active JP6423340B2 (ja) | 2012-05-15 | 2013-05-14 | 自己安定化リンカー結合体 |
| JP2018097123A Expired - Fee Related JP6709247B2 (ja) | 2012-05-15 | 2018-05-21 | 自己安定化リンカー結合体 |
| JP2020089453A Expired - Fee Related JP7014856B2 (ja) | 2012-05-15 | 2020-05-22 | 自己安定化リンカー結合体 |
| JP2022007056A Active JP7431261B2 (ja) | 2012-05-15 | 2022-01-20 | 自己安定化リンカー結合体 |
| JP2024014096A Pending JP2024032941A (ja) | 2012-05-15 | 2024-02-01 | 自己安定化リンカー結合体 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512756A Active JP6423340B2 (ja) | 2012-05-15 | 2013-05-14 | 自己安定化リンカー結合体 |
| JP2018097123A Expired - Fee Related JP6709247B2 (ja) | 2012-05-15 | 2018-05-21 | 自己安定化リンカー結合体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007056A Active JP7431261B2 (ja) | 2012-05-15 | 2022-01-20 | 自己安定化リンカー結合体 |
| JP2024014096A Pending JP2024032941A (ja) | 2012-05-15 | 2024-02-01 | 自己安定化リンカー結合体 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2850094B1 (https=) |
| JP (5) | JP6423340B2 (https=) |
| KR (5) | KR102557309B1 (https=) |
| CN (2) | CN108465112B (https=) |
| AU (5) | AU2013263002C1 (https=) |
| BR (1) | BR112014028222A2 (https=) |
| CA (2) | CA2869777C (https=) |
| EA (1) | EA037203B1 (https=) |
| ES (1) | ES2983109T3 (https=) |
| HK (1) | HK1207388A1 (https=) |
| MX (2) | MX384366B (https=) |
| NZ (3) | NZ724892A (https=) |
| SG (2) | SG11201406252WA (https=) |
| WO (1) | WO2013173337A2 (https=) |
| ZA (1) | ZA201407369B (https=) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| KR102557309B1 (ko) * | 2012-05-15 | 2023-07-20 | 씨젠 인크. | 자가-안정화 링커 접합체 |
| CA2927022C (en) | 2013-10-11 | 2018-08-21 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
| EA032231B1 (ru) | 2013-10-11 | 2019-04-30 | Мерсана Терапьютикс, Инк. | Конъюгаты белок-полимер-лекарственное средство |
| ES2826398T3 (es) | 2013-10-15 | 2021-05-18 | Seagen Inc | Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco |
| JP6701077B2 (ja) | 2013-12-19 | 2020-05-27 | シアトル ジェネティックス， インコーポレイテッド | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
| WO2016008112A1 (en) * | 2014-07-16 | 2016-01-21 | Medshine Discovery Inc. | Linkers and application towards adc thereof |
| SI3900742T1 (sl) * | 2014-09-11 | 2024-10-30 | Seagen Inc. | Ciljana dostava zdravilnih snovi, ki vsebujejo terciarne amine |
| JP6863888B2 (ja) * | 2014-10-01 | 2021-04-21 | メディミューン，エルエルシー | ポリペプチドをコンジュゲートさせる方法 |
| WO2016063959A1 (ja) | 2014-10-24 | 2016-04-28 | 日油株式会社 | 環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体 |
| MX2017007169A (es) * | 2014-12-03 | 2018-05-02 | Genentech Inc | Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos. |
| KR20170093943A (ko) * | 2014-12-09 | 2017-08-16 | 애브비 인코포레이티드 | 낮은 세포 투과성을 갖는 bcl xl 억제 화합물 및 이를 포함하는 항체 약물 접합체 |
| BR112017012342A2 (pt) * | 2014-12-09 | 2018-02-27 | Abbvie Inc | compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos |
| MX382582B (es) | 2015-03-18 | 2025-03-13 | Seagen Inc | Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados. |
| CN106267225B (zh) | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | 三马来酰亚胺型连接子及其应用 |
| CN111533778B (zh) * | 2015-07-28 | 2023-04-25 | 上海皓元生物医药科技有限公司 | 一种抗体偶联药物连接子的工业化生产方法 |
| US10689458B2 (en) | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| CN108367043A (zh) | 2015-12-04 | 2018-08-03 | 西雅图基因公司 | 季铵化的微管溶素化合物的缀合物 |
| KR20180134351A (ko) | 2016-03-25 | 2018-12-18 | 시애틀 지네틱스, 인크. | 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정 |
| US11091498B2 (en) | 2016-04-04 | 2021-08-17 | Rutgers, The State University Of New Jersey | Topoisomerase poisons |
| KR20190005924A (ko) * | 2016-05-10 | 2019-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | 향상된 안정성을 갖는 튜부리신 유사체의 항체-약물 접합체 |
| BR112018075639A2 (pt) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | conjugados de anticorpo fármaco anti-egfr |
| CN116173232A (zh) | 2016-06-08 | 2023-05-30 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
| CN109563168A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗egfr抗体药物偶联物 |
| EP3469000A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| BR112018075630A2 (pt) | 2016-06-08 | 2019-03-19 | Abbvie Inc. | anticorpos anti-cd98 e conjugados de fármaco de anticorpo |
| JP2019521975A (ja) | 2016-06-08 | 2019-08-08 | アッヴィ・インコーポレイテッド | 抗ｅｇｆｒ抗体薬物コンジュゲート |
| EP3458479B1 (en) | 2016-06-08 | 2020-11-04 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| BR112018075644A2 (pt) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | anticorpos anti-cd98 e conjugados de anticorpo e fármaco |
| MX2019001302A (es) * | 2016-08-09 | 2019-06-12 | Seattle Genetics Inc | Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas. |
| KR20240000650A (ko) | 2016-10-19 | 2024-01-02 | 인벤라 인코포레이티드 | 항체 구조물 |
| JP7244987B2 (ja) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
| EP3559039A1 (en) | 2016-12-22 | 2019-10-30 | Università Degli Studi Magna Graecia Catanzaro | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43 |
| AU2018237683A1 (en) | 2017-03-24 | 2019-10-31 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| CN107652219B (zh) | 2017-08-14 | 2021-06-08 | 上海新理念生物医药科技有限公司 | 四马来酰亚胺型连接子及其应用 |
| TW202428569A (zh) | 2017-09-08 | 2024-07-16 | 美商思進公司 | 妥布賴森(tubulysins)及其中間產物之製備方法 |
| WO2019051489A1 (en) * | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| WO2019217455A1 (en) | 2018-05-07 | 2019-11-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| WO2019234136A1 (en) | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| EP3897734A4 (en) * | 2018-12-21 | 2022-12-07 | Seagen Inc. | ADC COMPRISING MULTIPLEX THIOL LINKERS |
| CA3144790A1 (en) * | 2019-06-28 | 2020-12-30 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof |
| AU2020356955A1 (en) | 2019-10-04 | 2022-04-14 | Seagen Inc. | Camptothecin peptide conjugates |
| WO2021207701A1 (en) * | 2020-04-10 | 2021-10-14 | Seagen Inc. | Charge variant linkers |
| US20230201358A1 (en) * | 2020-05-08 | 2023-06-29 | Mpeg La, L.L.C. | Linker compounds |
| WO2022068898A1 (zh) * | 2020-09-29 | 2022-04-07 | 迈威(上海)生物科技股份有限公司 | 一种双取代桥连抗体偶联药物的制备方法 |
| EP4257153B1 (en) | 2020-12-04 | 2025-11-12 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| MX2024002571A (es) | 2021-09-03 | 2024-03-20 | Toray Industries | Composicion farmaceutica para tratamiento y/o prevencion de cancer. |
| WO2023091464A1 (en) | 2021-11-16 | 2023-05-25 | ProDeg, LLC | Usp9x inhibitors |
| IL315508A (en) | 2022-03-17 | 2024-11-01 | Seagen Inc | Camptothecin conjugates |
| KR20250031149A (ko) | 2022-06-30 | 2025-03-06 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
| TW202435916A (zh) * | 2022-10-28 | 2024-09-16 | 美商美國禮來大藥廠 | 用於生物結合之自體水解順丁烯二酼亞胺 |
| TW202435917A (zh) | 2022-11-17 | 2024-09-16 | 美商西雅圖遺傳學公司 | Ceacam5抗體-藥物接合物及其使用方法 |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| JP2026508145A (ja) * | 2023-02-09 | 2026-03-10 | ビーワン メディシンズ ワン ゲーエムベーハー | 自己安定化リンカーコンジュゲート |
| WO2024220889A1 (en) | 2023-04-20 | 2024-10-24 | Seagen Inc. | Sting agonist compounds and conjugates thereof |
| EP4727971A1 (en) | 2023-06-13 | 2026-04-22 | Adcentrx Therapeutics Inc. | Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins |
| TW202500198A (zh) * | 2023-06-29 | 2025-01-01 | 瑞士商百濟神州瑞士有限責任公司 | 生物活性偶聯物、其製備方法及用途 |
| WO2025054181A1 (en) | 2023-09-05 | 2025-03-13 | Seagen Inc. | Targeted degrader molecules and ligand drug conjugates thereof |
| AU2024339683A1 (en) | 2023-09-13 | 2026-03-26 | Toray Industries, Inc. | Pharmaceutical composition for treating, preventing and/or diagnosing cancer |
| AU2024339843A1 (en) | 2023-09-13 | 2026-04-23 | Astellas Pharma Inc. | Antibody-drug conjugate containing heterocyclic compound having G12D mutant KRAS protein degradation-inducing effect |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
| WO2025171055A1 (en) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Heterocyclic conjugates and uses thereof |
| WO2025264533A1 (en) | 2024-06-17 | 2025-12-26 | Adcentrx Therapeutics Inc. | Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins |
| WO2026055185A1 (en) | 2024-09-04 | 2026-03-12 | Bolt Biotherapeutics, Inc. | Sting agonist immunoconjugates and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5091542A (en) * | 1990-03-09 | 1992-02-25 | Hybritech Incorporated | Tris-maleimido compounds as intermediates in trifunctional antibody synthesis |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| WO1994001485A1 (en) * | 1992-07-01 | 1994-01-20 | Akzo Nobel N.V. | Process for the modification of polyphenylene ether resin compositions |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| US5973166A (en) | 1998-03-02 | 1999-10-26 | The Dexter Corporation | Method for the preparation of maleimides |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
| US8877901B2 (en) * | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| US7432331B2 (en) * | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| JP5171621B2 (ja) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス， インコーポレイテッド | フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物 |
| US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
| BRPI0617546A2 (pt) | 2005-09-26 | 2011-07-26 | Medarex Inc | conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto |
| SI1813614T1 (sl) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
| RU2476441C2 (ru) | 2007-10-19 | 2013-02-27 | Сиэтл Дженетикс, Инк. | Cd19-связывающие средства и их применение |
| EP2265283B1 (en) | 2008-03-18 | 2014-09-03 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| KR20200058590A (ko) | 2008-04-30 | 2020-05-27 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| BRPI0923283A2 (pt) * | 2008-12-05 | 2017-06-06 | Angiochem Inc | conjugados terapêuticos de peptídeo e usos dos mesmos |
| CN102365021B (zh) | 2009-02-05 | 2015-07-15 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
| EP3912643B8 (en) * | 2009-02-13 | 2023-08-23 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| AU2011316917B2 (en) * | 2010-10-22 | 2016-02-25 | Seagen Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway |
| JP6049642B2 (ja) | 2011-02-15 | 2016-12-21 | イミュノジェン・インコーポレーテッド | 複合体の調製方法 |
| KR102557309B1 (ko) * | 2012-05-15 | 2023-07-20 | 씨젠 인크. | 자가-안정화 링커 접합체 |
| EP2968591A1 (en) * | 2013-03-15 | 2016-01-20 | Novartis AG | Cell proliferation inhibitors and conjugates thereof |
-
2013
- 2013-05-14 KR KR1020227042635A patent/KR102557309B1/ko active Active
- 2013-05-14 AU AU2013263002A patent/AU2013263002C1/en not_active Ceased
- 2013-05-14 CN CN201810349815.9A patent/CN108465112B/zh active Active
- 2013-05-14 CA CA2869777A patent/CA2869777C/en active Active
- 2013-05-14 NZ NZ724892A patent/NZ724892A/en not_active IP Right Cessation
- 2013-05-14 KR KR1020207022850A patent/KR102433686B1/ko active Active
- 2013-05-14 CN CN201380025771.XA patent/CN104822656B/zh active Active
- 2013-05-14 KR KR1020147034652A patent/KR102144069B1/ko active Active
- 2013-05-14 NZ NZ630870A patent/NZ630870A/en not_active IP Right Cessation
- 2013-05-14 BR BR112014028222A patent/BR112014028222A2/pt not_active Application Discontinuation
- 2013-05-14 NZ NZ74121113A patent/NZ741211A/en not_active IP Right Cessation
- 2013-05-14 KR KR1020237024059A patent/KR20230113821A/ko not_active Ceased
- 2013-05-14 KR KR1020217023061A patent/KR102475777B1/ko active Active
- 2013-05-14 JP JP2015512756A patent/JP6423340B2/ja active Active
- 2013-05-14 ES ES13791383T patent/ES2983109T3/es active Active
- 2013-05-14 SG SG11201406252WA patent/SG11201406252WA/en unknown
- 2013-05-14 EP EP13791383.6A patent/EP2850094B1/en active Active
- 2013-05-14 MX MX2019012201A patent/MX384366B/es unknown
- 2013-05-14 SG SG10201608904YA patent/SG10201608904YA/en unknown
- 2013-05-14 HK HK15108030.8A patent/HK1207388A1/xx unknown
- 2013-05-14 CA CA3131619A patent/CA3131619A1/en not_active Abandoned
- 2013-05-14 MX MX2014013807A patent/MX368678B/es active IP Right Grant
- 2013-05-14 WO PCT/US2013/040951 patent/WO2013173337A2/en not_active Ceased
- 2013-05-14 EA EA201401254A patent/EA037203B1/ru unknown
-
2014
- 2014-10-10 ZA ZA2014/07369A patent/ZA201407369B/en unknown
-
2018
- 2018-02-19 AU AU2018201190A patent/AU2018201190B2/en not_active Ceased
- 2018-05-21 JP JP2018097123A patent/JP6709247B2/ja not_active Expired - Fee Related
-
2020
- 2020-04-28 AU AU2020202805A patent/AU2020202805B2/en not_active Ceased
- 2020-05-22 JP JP2020089453A patent/JP7014856B2/ja not_active Expired - Fee Related
-
2021
- 2021-03-16 AU AU2021201636A patent/AU2021201636B2/en not_active Ceased
-
2022
- 2022-01-20 JP JP2022007056A patent/JP7431261B2/ja active Active
-
2023
- 2023-05-15 AU AU2023203005A patent/AU2023203005A1/en not_active Abandoned
-
2024
- 2024-02-01 JP JP2024014096A patent/JP2024032941A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020122023A5 (https=) | ||
| JP6709247B2 (ja) | 自己安定化リンカー結合体 | |
| TWI804499B (zh) | Ror1抗體免疫接合物 | |
| JP7320455B2 (ja) | 親水性リンカーおよびそのコンジュゲート | |
| AU2023201373A1 (en) | Hydrophilic antibody-drug conjugates | |
| JP2023082171A (ja) | 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート | |
| JP5314590B2 (ja) | カンプトテシン結合部分 | |
| CN101969970B (zh) | 用抗体-药物偶联物联合治疗 | |
| JP2022528851A5 (https=) | ||
| CN112543752B (zh) | 连接子、含连接子的抗体偶联药物及连接子的用途 | |
| JP2015524796A5 (ja) | 細胞毒性剤と細胞結合受容体との共役体 | |
| JP7576779B2 (ja) | 抗体－ｓｔｉｎｇアゴニスト複合体および免疫療法におけるそれらの使用 | |
| JP7335957B2 (ja) | 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| KR20230008723A (ko) | 전하 변이체 링커 | |
| JP2015110667A (ja) | Ｄｒ５リガンド薬物結合体 | |
| JP2005521389A5 (https=) | ||
| WO1997046260A1 (fr) | Complexes medicamenteux | |
| JP2009529522A (ja) | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 | |
| JP7057391B2 (ja) | タンパク薬物複合体で使用するためのリンカーに関連する材料および方法 | |
| JP2023541969A (ja) | 可溶性タグを有する分子および関連方法 | |
| JPWO2020200880A5 (https=) | ||
| JP3340127B2 (ja) | 異常増殖性疾患措置のための抗体接合体 | |
| JP2024506300A (ja) | 免疫刺激化合物及びコンジュゲート体 | |
| JP2023159335A5 (https=) | ||
| CA3121573A1 (en) | Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof |